Total submissions: 9
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000706855 | SCV000835929 | pathogenic | Deafness-lymphedema-leukemia syndrome; Monocytopenia with susceptibility to infections | 2022-11-15 | criteria provided, single submitter | clinical testing | Experimental studies have shown that this missense change affects GATA2 function (PMID: 21892162, 25676417). For these reasons, this variant has been classified as Pathogenic. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt GATA2 protein function. ClinVar contains an entry for this variant (Variation ID: 29711). This missense change has been observed in individual(s) with GATA2 deficiency and myelodysplastic syndrome and acute myeloid leukemia (PMID: 21670465, 21892162, 23365458). It has also been observed to segregate with disease in related individuals. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces threonine, which is neutral and polar, with methionine, which is neutral and non-polar, at codon 354 of the GATA2 protein (p.Thr354Met). |
Prevention |
RCV000984820 | SCV001132702 | pathogenic | not provided | 2015-07-23 | criteria provided, single submitter | clinical testing | |
Molecular Pathology Research Laboratory, |
RCV001542226 | SCV001760894 | pathogenic | Deafness-lymphedema-leukemia syndrome; GATA2 deficiency with susceptibility to MDS/AML | 2021-07-06 | criteria provided, single submitter | curation | PS3, PS4, PM1, PM2, PM5, PP1_Strong, PP3 |
Gene |
RCV000984820 | SCV001785631 | pathogenic | not provided | 2022-06-13 | criteria provided, single submitter | clinical testing | Published functional studies demonstrate a damaging effect: NK-cell deficiency, reduced transactivation activity, reduced DNA binding activity (Hahn 2011, Kazenwadel 2012, Mace 2013, Hahn 2015); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 29749400, 23365458, 25676417, 21892162, 22147895, 21765025, 29588856, 30232126, 31035956, 32098966, 24227816, 21670465, 23223431, 24754962, 22533337, 22271902, 27577878, 1714909, 28179282, 33510405, 32888943) |
Clinical Genetics Laboratory, |
RCV000984820 | SCV005198010 | pathogenic | not provided | 2022-05-27 | criteria provided, single submitter | clinical testing | |
OMIM | RCV000022561 | SCV000043850 | pathogenic | Monocytopenia with susceptibility to infections | 2011-09-08 | no assertion criteria provided | literature only | |
OMIM | RCV000022562 | SCV000043851 | risk factor | Myelodysplastic syndrome | 2011-09-08 | no assertion criteria provided | literature only | |
OMIM | RCV000022563 | SCV000043852 | risk factor | Leukemia, acute myeloid, susceptibility to | 2011-09-08 | no assertion criteria provided | literature only | |
Database of Curated Mutations |
RCV000426616 | SCV000504647 | likely pathogenic | Acute myeloid leukemia | 2014-10-02 | no assertion criteria provided | literature only |